Bio Insight
The Frontier That Won’t Quite Arrive
Ask the region’s clinical-operations leaders whether decentralised and hybrid trials are the future, and the answer is almost unanimous. Surveys keep...
June 26, 2026 | Analysis
Vendor to Co-Innovator — or Bring It In-House? The CDMO Relationship Rewires
For two decades the contract development and manufacturing organisation occupied a comfortable, clearly understood place in the biopharma value chain. The ...
June 25, 2026 | Analysis
Security at What Cost? APAC and the Great Supply-Chain Reordering
For the better part of two decades, the global pharmaceutical supply chain ran on a simple, unsentimental bargain: make the chemistry where it is cheapest,...
June 24, 2026 | Analysis
After the Drug Substance, the Real Squeeze: APAC's Aseptic Fill-Finish Gap
For most of the last decade, the anxiety in Asia-Pacific biomanufacturing pointed upstream. The conversation was about bioreactor volume — how many t...
June 22, 2026 | Analysis
Billions on Bioconjugation: Is APAC Building the Right ADC Capacity — or Too Much?
In Songdo, on the reclaimed waterfront west of Seoul, a 202,000-square-metre construction site is becoming the most expensive single statement Kore...
June 19, 2026 | Analysis
World-Class Plants, Who Will Run Them? APAC's Biomanufacturing Skills Gap
Walk into one of the gleaming new large-molecule plants going up across Songdo, Tuas or Hyderabad and the first impression is of inevitability. The...
June 18, 2026 | Analysis
Agility or Corner-Cutting? Asia's Accelerated-Approval Gamble
On 1 April 2026, Japan's Pharmaceuticals and Medical Devices Agency did something no other major medicines regulator had done before it: from that date, ev...
June 17, 2026 | Analysis
Good Enough and Cheap, or Prove It's Equivalent? Asia's Biosimilar Trust Gap
There is a number that captures Asia's biosimilar paradox in a single line. According to Samsung Bioepis's quarterly tracking of the United States market, ...
June 15, 2026 | Analysis
AI Must Shift Healthcare From Crisis Response To Early Intervention Across APAC
As healthcare systems across Asia Pacific confront mounting workforce shortages, ageing populations, and rising chronic disease burdens, artificial intelli...
June 10, 2026 | News
Can the 'Pharmacy of the World' Survive Its Own Scandals?
In late September and early October 2025, children in the central Indian state of Madhya Pradesh began arriving at hospitals with the same grim trajectory:...
June 08, 2026 | Analysis
The Footnote Test: When the Sustainability Pledge Met the Earnings Call
The slide had been on the screen for almost a minute, and no one in the room would meet its eye. It was a simple chart, the kind that the company's invest...
June 04, 2026 | Analysis
Curative but Unaffordable: Gene and Cell Therapy's Access Paradox in Asia
At almost every cell-and-gene-therapy conference in the region, the same slide appears: a child who was dying of leukaemia, now in durable remission; a tee...
June 03, 2026 | Analysis
Advancing NAD Biomarkers From Research Discovery To Clinical Reality
As interest in metabolic health, longevity science, and precision medicine continues to grow, the ability to accurately measure biological markers linked t...
June 03, 2026 | Interview
Innovation Powerhouse or Inflated Bubble? Reading China’s First-in-Class Boom
A decade ago, the phrase “Chinese first-in-class drug” would have drawn a raised eyebrow in any Western boardroom. China made generics, copied ...
June 02, 2026 | Analysis | By arcilla.fran@biopharmaapac.com
Most Read
- Can APAC Biomanufacturing Decarbonise Without Pricing Itself Out?
- The Algorithm on the GMP Floor: AI Promises a Smarter Plant. Regulators Demand the Audit Trail.
- APAC's Peptide-Capacity Gamble
- After the Rush: APAC's mRNA and Vaccine Capacity Hangover
- The Biosimilar Race: Factory to the World — or Stuck in the Copycat Economy?
- The Vein-to-Vein Problem: Can APAC's Cold Chain Carry Advanced Therapies?
- Vectors, Plasmids and the CGT Trap: APAC's Cell and Gene Therapy Ambitions Face an Upstream Bottleneck
- Can APAC Build Radioligand Therapy Before the Atoms Decay?
- The Great Biopharma Reset: 50 Developments That Changed Everything in H1 2026
- Beyond the Trial: Can Real-World Evidence Earn Regulatory Trust in APAC?
- Beyond the Obvious Giant: Where APAC's Clinical Trials Go Next
- The Frontier That Won’t Quite Arrive
Bio Jobs
- Sanofi Turns The Page As Belén Garijo Steps In And Paul Hudson Steps Out
- Global Survey Reveals Nearly 40% of Employees Facing Fertility Challenges Consider Leaving Their Jobs
- BioMed X and AbbVie Begin Global Search for Bold Neuroscience Talent To Decode the Biology of Anhedonia
- Thermo Fisher Expands Bengaluru R&D Centre to Advance Antibody Innovation and Strengthen India’s Life Sciences Ecosystem
- Accord Plasma (Intas Group) Acquires Prothya Biosolutions to Expand Global Plasma Capabilities
- ACG Announces $200 Million Investment to Establish First U.S. Capsule Manufacturing Facility in Atlanta
- AstraZeneca Invests $4.5 Billion to Build Advanced Manufacturing Facility in Virginia, Expanding U.S. Medicine Production
News
